For Health Care Professionals Outside the US
Find a Centre
Find a Centre
ALL1
I Am KYMRIAH

Because

I want to empower my own immune system to fight ALL1
I want a CAR-T treatment with the potential to put my ALL in remission
I have lots of living left to do

KYMRIAH® (tisagenlecleucel) is indicated for the treatment of:
  • Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
  • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
KYMRIAH: The first CAR-T cell therapy approved for paediatric and young adult ALL1
  • High rates of remission
  • Compelling survival data
  • Potentially curative treatment
Reference:
  • 1.Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2020.